Abstract / Description
IntroductionIndividuals with co-morbid T2D and IBD represent a uniquely high-risk group, facing amplified cardiovascular risk through synergistic inflammatory and metabolic pathways, in whom conventional cardiometabolic strategies (such as dietary and lifestyle changes, weight loss, blood pressure and lipid optimization, metformin therapy, SGLT2 inhibitor therapy) may be insufficient due to the overlap between metabolic disease and chronic inflammatory disease processes. At present, the literature available on the role of incretin-based therapy in the treatment of T2D in patients with co-morbid IBD is limited. We aimed to evaluate the association of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists with cardiovascular outcomes in individuals with T2DM and IBD. This study is not intended as a direct comparison of the efficacy of GLP-1 agonists and dual GLP-1/GIP receptor agonists in patients with T2D and IBD. Both drug classes were analyzed as a combined incretin-based therapy exposure group to reflect real-world prescribing patterns and maximize statistical power.MethodsWe conducted a retrospective cohort study using the TriNetX global federated research network, identifying adults (ā„18 years) with T2D and IBD between 2015-2024. Patients prescribed GLP-1 or dual GLP-1/GIP were compared with non-users following 1:1 propensity score matching on demographics, comorbidities, and medication use. Relative risks (RR) and Hazard Ratios (HR) with 95% confidence intervals (CI) were calculated, with significance defined as pā